MedDataX Logo

Study of the Relationship Between rHuEPO Dose, Serum ADPN, and Mortality in Patients Beginning Hemodialysis (HD)

NCT ID: NCT00308698

Last Updated: 2006-03-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Study Classification

OBSERVATIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

High recombinant human erythropoietin requirement and elevated serum adiponectin were significant determinants of long-term mortality in patients who started hemodialysis therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background: Responsiveness of recombinant human erythropoietin (rHuEPO) is known to be related with body fatness in hemodialysis (HD) patients. Adiponectin (ADPN) is inversely associated with body fat mass, and in healthy subjects, low ADPN is a predictor of mortality. Recently, higher rHuEPO dose itself is demonstrated to be associated with poor prognosis. So, in this study, we prospectively examined the relationship between rHuEPO dose, serum ADPN, and mortality in patients beginning HD.

Methods: We selected 85 patients (51 men/34 women, age; 64±15 years) who survived for more than 3 months after the start of HD. After determining initial rHuEPO dosage, we followed the patients for 3 years, and examined an association between rHuEPO dose, serum ADPN, and all-cause mortality.

Results: We could follow totally 74 out of 85 patients for 3 years; 59 patients were survived, but 15 patients expired. Dosage of rHuEPO was significantly and negatively correlated with body mass index (BMI) (r=-0.44, p\<0.01) and positively with serum ADPN (r=0.29, p\<0.02), but not with leptin. Cox-hazards regression analysis adjusted by age, sex and underlying kidney disease revealed that rHuEPO dose and serum ADPN, as well as nutritional parameter such as protein catabolic rate became significant determinants of 3-year mortality. There was a 12.7% risk increase for 10U/kg/week increase in rHuEPO dose and 1.3% increase for 1µg/ml increment of serum ADPN for the 3-year of follow-up.

Conclusion: High rHuEPO requirement and elevated serum ADPN were significant determinants of long-term mortality in patients who started HD therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Dialysis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

recombinant human erythropoietin adiponectin mortality

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

DEFINED_POPULATION

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients who had first started hemodialysis therapy from August 2000 to May 2001 in 11 dialysis centers in Shizuoka prefecture area.

Exclusion Criteria

* nothing particular
Minimum Eligible Age

0 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fujinomiya City Hospital

OTHER

Sponsor Role collaborator

Iwata City Hospital

OTHER

Sponsor Role collaborator

Seirei Mikatabara General Hospital

UNKNOWN

Sponsor Role collaborator

Seirei Hamamatsu General Hospital

OTHER

Sponsor Role collaborator

Hamana Clinic

OTHER

Sponsor Role collaborator

Tadokoro Clinic

UNKNOWN

Sponsor Role collaborator

Makoto Clinic

UNKNOWN

Sponsor Role collaborator

Maruyama Memorial General Hospital

OTHER

Sponsor Role collaborator

Shitoro Clinic

UNKNOWN

Sponsor Role collaborator

Sun-Sanaru Clinic

UNKNOWN

Sponsor Role collaborator

Hamamatsu University

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Naro Ohashi, M.D., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

First Department of Medicine, Hamamatsu University School of Medicine

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0808

Identifier Type: -

Identifier Source: org_study_id